{
  "source": "PA-Notification-Zilbrysq.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1428-2\nProgram Prior Authorization/Notification\nMedication Zilbrysq® (zilucoplan)\nP&T Approval Date 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nZilbrysq (zilucoplan) is a complement inhibitor indicated for the treatment of generalized\nmyasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody\npositive.1\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Zilbrysq will be approved based on all of the following criteria:\na. Diagnosis of generalized myasthenia gravis (gMG)\n-AND-\nb. Positive serologic test for anti-AChR antibodies\n-AND-\nc. Patient is not receiving Zilbrysq in combination with another complement inhibitor\n[e.g., Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)] or a neonatal Fc receptor\nblocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab),\nVyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Zilbrysq will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Zilbrysq therapy\n-AND-\nb. Patient is not receiving Zilbrysq in combination with another complement inhibitor\n[e.g., Soliris (eculizumab), Ultomiris (ravulizumab-cwvz)] or a neonatal Fc receptor\nblocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab),\nVyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)]\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.",
    "al Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may also be in place.\n4. References:\n1. Zilbrysq [package insert], Smyrna, GA: UCB, Inc.; April 2024.\nProgram Prior Authorization/Notification - Zilbrysq® (zilucoplan)\nChange Control\n1/2024 New program.\n1/2025 Annual review. Updated listing of examples of complement inhibitors and\nneonatal Fc receptor blockers without change to clinical intent. Updated\nreference.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}